ID: h-f9c6fa3f
Hypothesis
Microbiome-Derived Tryptophan Metabolite Neuroprotection
Beneficial gut bacteria convert dietary tryptophan into neuroprotective metabolites like indole-3-propionic acid, which activate aryl hydrocarbon receptors in microglia, shifting them from pro-inflammatory to anti-inflammatory phenotypes.
EvidencePending (0%)📖 18 cit🗣 1 debates✓ 5 support✗ 2 oppose
✓ All Quality Gates Passed
🧪 Overview
Beneficial gut bacteria convert dietary tryptophan into neuroprotective metabolites like indole-3-propionic acid, which activate aryl hydrocarbon receptors in microglia, shifting them from pro-inflammatory to anti-inflammatory phenotypes. Precision probiotic therapy could restore this protective pathway.
🧬 Mechanism
🧬 Curated Mechanism Pathway
Curated pathway from expert analysis
graph TD
A["Tryptophan Dietary Intake"] -->|"substrate"| B["Gut Microbiome Metabolism"]
B -->|"produces"| C["Indole-3-Propionic Acid"]
C -->|"crosses BBB via MCT1/MCT2"| D["CNS Entry"]
D -->|"ligand binding"| E["AHR Activation"]
E -->|"transcriptional regulation"| F["IL10 Gene Expression"]
E -->|"transcriptional regulation"| G["TGFB1 Gene Expression"]
F -->|"anti-inflammatory"| H["Microglial M2 Polarization"]
G -->|"immunosuppressive"| H
H -->|"reduces"| I["Neuroinflammation"]
I -->|"prevents"| J["Synaptic Loss"]
I -->|"prevents"| K["Neuronal Death"]
L["Dysbiosis"] -->|"reduces"| B
M["Probiotic Therapy"] -->|"restores"| B
N["AHR Agonists"] -->|"activates"| E
O["Neuroprotection"]
J -->|"maintains"| O
K -->|"maintains"| O
classDef mechanism fill:#4fc3f7,color:#0d0d1a
classDef pathology fill:#ef5350,color:#0d0d1a
classDef therapy fill:#81c784,color:#0d0d1a
classDef outcome fill:#ffd54f,color:#0d0d1a
classDef genetics fill:#ce93d8,color:#0d0d1a
class A,C,D,E mechanism
class L,I,J,K pathology
class M,N therapy
class O outcome
class B,F,G,H genetics⚖️ Evidence
⚖️ Evidence Matrix5 supports2 contradicts
Supports
Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma.
Supports
Sex-dependent APOE4 neutrophil-microglia interactions drive cognitive impairment in Alzheimer's disease.
Supports
Microbiota-indole 3-propionic acid-brain axis mediates abnormal synaptic pruning of hippocampal microglia and susceptibility to ASD in IUGR offspring.
Supports
Paeonol alleviates neuropathic pain by modulating microglial M1 and M2 polarization via the RhoA/p38MAPK signaling pathway.
Supports
Microglia-specific IL-10 gene delivery inhibits neuroinflammation and neurodegeneration in a mouse model of Parkinson's disease.
Contradicts
Indole metabolite neuroprotection has been shown in amyloidopathy contexts, but this does not prove generalizable protection across neurodegenerative diseases or precision probiotic efficacy.
Contradicts
A comprehensive Parkinson review frames indole metabolites as an emerging and complex area rather than settled clinical neuroprotection.
📖 Linked Papers (15)Export BibTeX ↗
Physiologic maturation is both extrinsically and intrinsically regulated in progenitor-derived neurons.
Scientific reports (2020) · PubMed:32047174 ↗
5 figures

Figure 1
Progenitor-derived neurons cultured for 7 days in vitro (DIV) exhibited immature responses to GABA A receptor activation. ( a – c ) Representative pictures o...

Figure 2
KCC2 expression is low in progenitor-derived neurons by 7 DIV. ( a ) Little KCC2 immunofluorescence was observed in progenitor-derived neurons and P5 RGCs compa...
Targeting Aryl hydrocarbon receptor for next-generation immunotherapies: Selective modulators (SAhRMs) versus rapidly metabolized ligands (RMAhRLs).
European journal of medicinal chemistry (2020) · PubMed:31727470 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
ilastik: interactive machine learning for (bio)image analysis.
Nature methods (2019) · PubMed:31570887 ↗
1 figure
Figures
Figures available at source paper (no open-access XML found).
Gut microbiota-derived indoleacetic acid attenuates neuroinflammation and neurodegeneration in glaucoma through ahr/rage pathway.
J Neuroinflammation (2025) · PubMed:40640940 ↗
No figures
A review on immunomodulatory effects of BPA analogues.
Archives of toxicology (2023) · PubMed:37204436 ↗
No figures
The Aryl Hydrocarbon Receptor: A Mediator and Potential Therapeutic Target for Ocular and Non-Ocular Neurodegenerative Diseases.
International journal of molecular sciences (2020) · PubMed:32947781 ↗
No figures
Gene editing.
Nature biotechnology (2020) · PubMed:32641840 ↗
No figures
Single-cell reconstruction of the adult human heart during heart failure and recovery reveals the cellular landscape underlying cardiac function.
Nature cell biology (2020) · PubMed:31915373 ↗
No figures
[Effect of alexithymia on health anxiety: Mediating role of cognition and meta-cognition].
Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences (2018) · PubMed:30333296 ↗
No figures
Incorporation of oxygen atoms as a mechanism for photoluminescence enhancement of chemically treated MoS
Physical chemistry chemical physics : PCCP (2018) · PubMed:29904778 ↗
No figures
Nicotinamide mononucleotide attenuates brain injury after intracerebral hemorrhage by activating Nrf2/HO-1 signaling pathway.
Scientific reports (2017) · PubMed:28386082 ↗
No figures
📙 Related Wiki Pages (15)
IL10 — Interleukin 10geneTGFB1 — Transforming Growth Factor Beta geneSynaptic Biomarkers in NeurodegenerationbiomarkerExosomal miR-155 in NeurodegenerationbiomarkerNeuroimaging Biomarkers for NeurodegenerbiomarkerMDS 2026 — Fluid Biomarker Advances in NeventCSF Neurofilament Light Chain (NfL) in NbiomarkerBlood-Based Biomarkers for NeurodegenerabiomarkerDNA Methylation Biomarkers in NeurodegenbiomarkerExosomal Biomarkers in NeurodegenerationbiomarkerMetabolomic Biomarkers in NeurodegeneratbiomarkerIL-6 (Interleukin-6) in NeurodegeneratiobiomarkerCell-Free DNA Biomarkers in NeurodegenerbiomarkerLiquid Biopsy in NeurodegenerationbiomarkerGlutamate - Excitotoxicity and Neurodegebiomarker
🏥 Translation
🧬 3D Protein Structure — AHR
No curated PDB or AlphaFold mapping for AHR yet. Search RCSB →
💉 Clinical Trials (5)Relevance: 44%
0
Active
Active
0
Completed
Completed
282
Total Enrolled
Total Enrolled
PHASE1
Highest Phase
Highest Phase
RAPA-501 Therapy for ALSPHASE2
RECRUITING·NCT04220190 · Rapa Therapeutics LLC
41 enrolled · 2025-01-02 · → 2026-07-01
RAPA-501-ALS is a phase 2/3 expansion cohort study of RAPA-501 autologous hybrid TREG/Th2 cells in patients living with amyotrophic lateral sclerosis (pwALS).
Amyotrophic Lateral Sclerosis
RAPA-501 Autologous T stem cells
COMPLETED·NCT03955380 · Prof. Dr. Dieter Willbold
24 enrolled · 2018-12-12 · → 2019-04-03
This is a single-center multiple-ascending-dose clinical trial assessing the safety and tolerability of oral dosing of Contraloid acetate in healthy volunteers. The study drug Contraloid (alias RD2, a
Alzheimer Dementia Alzheimer Disease
Contraloid
UNKNOWN·NCT04820881 · Washington D.C. Veterans Affairs Medical Center
60 enrolled · 2021-10-01 · → 2024-09
This grant award entitled, "Cerebrovascular Reactivity and Oxygen Metabolism as Markers for Neurodegeneration after Traumatic Brain Injury" (hereafter, "Neurovascular Study"), aims to determine if neu
Neurodegenerative Diseases
Stereotactic Intracerebral Injection of Allogenic IPSC-DAPs in Patients With Parkinson's DiseasePHASE1
NOT_YET_RECRUITING·NCT07212088 · iCamuno Biotherapeutics Ltd.
12 enrolled · 2026-02-28 · → 2027-12-15
Parkinson's disease is a progressive neurodegenerative disorder characterized by high morbidity due to the limited regenerative capacity of dopaminergic neurons in the brain. Current drug treatments p
Parkinson Disease
ALC01 therapy
COMPLETED·NCT02405182 · University of Alberta
145 enrolled · 2014-09 · → 2019-03
Amyotrophic lateral sclerosis (ALS) is a disabling and rapidly progressive neurodegenerative disorder. There is no treatment that significantly slows progression. Increasing age is an important risk f
Amyotrophic Lateral Sclerosis ALS Motor Neuron Diseases
Magnetic Resonance Imaging
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for AHR, IL10, TGFB1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
💰 Estimated Development
Cost
$0
Timeline
2.2 years
🏆 Tournament
🏆 Arenas / Elo
No arena matches recorded yet. Browse Arenas →
📊 Market Indicators
7d Trend
↔
Stable
7d Momentum
▲ 0.4%
Volatility
High
0.0754
Events (7d)
2
Price History
▼24.4%💾 Resource Usage
LLM Tokens
34,972
$0.2158
Total Cost
$0.2158
🔮 Predictions
🔎 Predictions vs Observations3 predictions · 0 with recorded observations
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| If hypothesis is true, intervention identify patients most likely to benefit from intervention | identify patients most likely to benefit from intervention | — no observation — | pending | 0.30 |
| If hypothesis is true, intervention enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokinetic pa | enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokineti | — no observation — | pending | 0.30 |
| If hypothesis is true, intervention incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals | incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals | — no observation — | pending | 0.30 |
🔮 Falsifiable Predictions (3)
pendingconf 30%
If hypothesis is true, intervention identify patients most likely to benefit from intervention
Predicted outcome: identify patients most likely to benefit from intervention
Falsification: Intervention fails to identify patients most likely to benefit from intervention
pendingconf 30%
If hypothesis is true, intervention incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals
Predicted outcome: incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or externa
Falsification: Intervention fails to incorporate biosafety switches, enhanced colonization factors, and inducible metabolite production systems responsive to disease biomarkers or external signals
pendingconf 30%
If hypothesis is true, intervention enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokinetic parameters
Predicted outcome: enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and phar
Falsification: Intervention fails to enroll 40-60 participants across dose-escalation cohorts, with primary endpoints focusing on tolerability, microbiome engraftment efficiency, and pharmacokinetic parameters
▸Metadatasource: v1_phase_c_backfill · origin_type: gap_debate
| source | v1_phase_c_backfill |
| origin_type | gap_debate |
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
0%
Debates
0
Incoming
0
Outgoing
0
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.